Intranasal Ketamine for Late-Life Depression and Suicidal Ideation
Status:
Withdrawn
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The investigators of this study plan to investigate the feasibility and efficacy of repeated
doses of intranasal ketamine in severely depressed patients who are at least 65 years of age
and experiencing suicidal ideation. The results of the study could lead to development of new
strategies for treating depression.